Use Of A Hydroximic Acid Halide Derivative In The Treatment Of Neurodegenerative Diseases
The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl !-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
1 . Use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the racemic or optically active compound in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
2 . An use as claimed in claim 1 wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.
3 . An use as claimed in claim 2 wherein the chemical substance is a salt of (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.
4 . An use as claimed in claim 3 wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate.
5 . An use as claimed in any of claims 1 to 4 wherein the neurodegenerative disease is amyotrophic lateral sclerosis.
6 . Method of treatment or prevention of a neurodegenerative disease wherein a therapeutically effective amount of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the racemic or optically active compound is administered to a patient.
7 . A method as claimed in claim 6 wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.
8 . A method as claimed in claim 7 wherein the chemical substance is a salt of (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carbox-imidoyl chloride.
9 . A method as claimed in claim 8 wherein the chemical substance is (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate.
10 . A method as claimed in any of claims 6 to 9 wherein the neurodegenerative disease is amyotrophic lateral sclerosis.